
PMN Stock Forecast & Price Target
PMN Analyst Ratings
Bulls say
ProMIS Neurosciences Inc. has demonstrated a positive outlook, particularly with its Alzheimer’s candidate, PMN310, which has shown a favorable safety profile lacking amyloid-related imaging abnormalities (ARIA) in clinical trials, potentially positioning it as a safer alternative to other marketed anti-amyloid antibodies. The company has successfully advanced PMN310 to over 85% enrollment in its Phase Ib PRECISE-AD study, with upcoming 6-month data expected to be released in Q2 2026, further underpinning investor confidence. The Alzheimer’s market represents a substantial and rapidly expanding commercial opportunity, providing a compelling backdrop for ProMIS's growth prospects as it continues to innovate within the biotechnology realm.
Bears say
ProMIS Neurosciences Inc reported a net loss of $11.6 million for the third quarter of 2025, equating to a loss of $0.24 per share, indicating ongoing financial concerns that are characteristic of clinical-stage biotechnology firms. The company faces significant challenges including potential partnership risks, increased competition affecting market uptake, and the risk of dilution due to future financing needs before achieving cash flow positive status. Additionally, the lack of demonstrated efficacy and safety for its lead candidate, PMN310, amidst a competitive landscape poses substantial regulatory and commercial risks that contribute to the negative outlook for the company's stock.
This aggregate rating is based on analysts' research of ProMIS Neurosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
PMN Analyst Forecast & Price Prediction
Start investing in PMN
Order type
Buy in
Order amount
Est. shares
0 shares